HighTower Advisors
HTGM

HighTower Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

HighTower Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-63
Closed -$57K – 2412
2018
Q3 		$57K Buy
+63
New +$41.6K ﹤0.01% 2113

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HighTower Advisors's HTGM Position: Q4 2018 in Review

HighTower Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2018, closing a stake of 63 shares — an estimated $57K sold.

HighTower Advisors first reported a position in HTGM in Q3 2018 and held it in 1 quarter. The position peaked at $57K in Q3 2018. 48 funds tracked by Wall St. Rank hold HTGM as of Q4 2018.

  • HighTower Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • HighTower Advisors sold 63 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2018, an estimated $57K.
  • HighTower Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • HighTower Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $57K in Q3 2018.
  • 48 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2018.

Based on HighTower Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.